公开(公告)号：US08846865B2

公开(公告)日：2014-09-30

申请号：US13390033

申请日：2010-08-24

申请人： Yves Briers ,  Rob Lavigne ,  Maarten Walmagh ,  Stefan Miller

发明人： Yves Briers ,  Rob Lavigne ,  Maarten Walmagh ,  Stefan Miller

IPC分类号： A61K38/43 ,  C07K14/00 ,  C12N9/26 ,  A61K38/00 ,  A61K38/04 ,  C12N9/36

CPC分类号： C12N9/2462 ,  A01N43/50 ,  A23L3/3571 ,  A61K38/00 ,  A61K38/47 ,  C07K7/08 ,  C07K14/195 ,  C07K14/21 ,  C07K14/43518 ,  C07K2319/21 ,  C07K2319/55 ,  C12Q1/04 ,  C12Q1/34 ,  C12Y302/01017 ,  G01N2333/928

摘要： The present invention relates to a polypeptide with an amino acid sequence according to SEQ ID NO: 1 and fragments or derivatives thereof. The present invention further relates to fusion proteins comprising said polypeptide and an additional peptide stretch fused to said polypeptide at the N- or C-terminus. Moreover, the present invention relates to nucleic acid molecules encoding said polypeptide or fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, the present invention relates to said polypeptide or fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means, as cosmetic substance or as sanitizing agent. The present invention also relates to the use of said polypeptide or fusion protein for the treatment or prevention of Gram-negative bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries. Furthermore, the present invention relates to a pharmaceutical composition comprising said polypeptide or fusion protein.

摘要翻译： 本发明涉及具有根据SEQ ID NO：1的氨基酸序列及其片段或衍生物的多肽。 本发明还涉及包含所述多肽的融合蛋白和在N-或C-末端与所述多肽融合的另外的肽拉伸。 此外，本发明涉及编码所述多肽或融合蛋白的核酸分子，包含所述核酸分子的载体和包含所述核酸分子或所述载体的宿主细胞。 此外，本发明涉及用作药物的所述多肽或融合蛋白，特别是用于治疗或预防革兰氏阴性细菌感染，作为诊断手段，作为化妆品或消毒剂。 本发明还涉及所述多肽或融合蛋白用于治疗或预防食品的食品加工设备，食品加工厂，与食品接触的表面，医疗器械的革兰氏阴性细菌污染， 在医院和手术中的表面。 此外，本发明涉及包含所述多肽或融合蛋白的药物组合物。

公开(公告)号：US20130344055A1

公开(公告)日：2013-12-26

申请号：US13997058

申请日：2011-12-23

申请人： Yves Briers ,  Rob Lavigne ,  Maarten Walmagh ,  Stefan Miller

发明人： Yves Briers ,  Rob Lavigne ,  Maarten Walmagh ,  Stefan Miller

IPC分类号： A01N37/46 ,  C12Q1/37 ,  C12N9/54 ,  C12N9/52

CPC分类号： A01N37/46 ,  A61K38/00 ,  C07K2319/00 ,  C12N9/2462 ,  C12N9/52 ,  C12N9/54 ,  C12Q1/37 ,  Y02A50/469 ,  Y02A50/475 ,  Y02A50/478

摘要： The present invention relates to a fusion protein composed of an enzyme having the activity of degrading the cell wall of Gram-negative bacteria and/or Gram-positive bacteria and at least two peptide stretches fused to the enzyme at the N- or C-terminus, wherein the peptide stretches are distinct and selected from the group of synthetic amphiphatic peptide, synthetic cationic peptide, synthetic polycationic peptide, synthetic hydrophobic peptide, or naturally occurring antimicrobial peptide, like sushi peptide and defensin. Moreover, the present invention relates to nucleic acid molecules encoding said fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, the present invention relates to said fusion protein for use as a medicament, diagnostic means, cosmetic substance, a disinfectant or a food additive. The present invention also relates to the treatment or prevention of Gram-positive and/or Gram-negative bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries.

摘要翻译： 本发明涉及由具有降解革兰氏阴性细菌和/或革兰氏阳性细菌的细胞壁的活性的酶组成的融合蛋白，以及在N-或C-末端与酶融合的至少两个肽段 其中肽延伸是不同的，并且选自合成的两性肽，合成阳离子肽，合成聚阳离子肽，合成疏水性肽或天然存在的抗微生物肽，如寿司肽和防御素。 此外，本发明涉及编码所述融合蛋白的核酸分子，包含所述核酸分子的载体和包含所述核酸分子或所述载体的宿主细胞。 此外，本发明涉及用作药物，诊断方法，化妆品，消毒剂或食品添加剂的所述融合蛋白。 本发明还涉及治疗或预防食品加工设备，食品加工厂，与食品接触的表面，医疗器械的表面的革兰氏阳性和/或革兰氏阴性细菌污染 医院和手术。

公开(公告)号：US20110243915A1

公开(公告)日：2011-10-06

申请号：US13061053

申请日：2009-08-25

申请人： Yves Briers ,  Rob Lavigne ,  Guido Volckaert

发明人： Yves Briers ,  Rob Lavigne ,  Guido Volckaert

IPC分类号： A61K38/46 ,  C12N9/14 ,  C12N15/55 ,  C12N15/63 ,  C12N1/21 ,  C12N1/19 ,  A01N37/18 ,  C12Q1/34 ,  A61P31/04 ,  A01P1/00

CPC分类号： C12N9/2462 ,  A61K38/00 ,  C12N9/52 ,  Y02A50/473 ,  Y02A50/475 ,  Y02A50/478 ,  Y02A50/479 ,  Y02A50/481

摘要： The present invention relates to endolysin variants comprising an endolysin to which a peptide stretch with membrane or LPS disrupting activity is fused. Moreover, the present invention relates to nucleic acid molecules encoding said modified endolysin variant, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, the present invention relates to a method for producing said endolysin variant. Further, the present invention relates to said modified endolysin variant for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means, disinfectant or as cosmetic substance. The present invention also relates to the removal or reduction or prevention of Gram-negative bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries. Furthermore, the present invention relates to the use of said endolysin variant as a diagnostic means in medicinal, food or feed or environmental diagnostic. Finally, the present invention relates to a pharmaceutical composition comprising said modified endolysin variant

摘要翻译： 本发明涉及包含溶解有膜或LPS破坏活性的肽的细胞内溶素的细胞内溶素变体。 此外，本发明涉及编码所述修饰的内溶素变体的核酸分子，包含所述核酸分子的载体和包含所述核酸分子或所述载体的宿主细胞。 此外，本发明涉及一种生产所述细胞内溶素变体的方法。 此外，本发明涉及用作药物，特别是用于治疗或预防革兰氏阴性细菌感染的所述修饰的内溶素变体作为诊断手段，消毒剂或化妆品物质。 本发明还涉及去除或减少食品加工设备，食品加工设备，与食品接触的表面，医疗设备，医院和手术中的表面的革兰氏阴性细菌污染物。 此外，本发明涉及所述细胞内溶素变体作为药物，食品或饲料或环境诊断中的诊断方法的用途。 最后，本发明涉及包含所述修饰的内溶素变体的药物组合物

公开(公告)号：US09809808B2

公开(公告)日：2017-11-07

申请号：US13061053

申请日：2009-08-25

申请人： Yves Briers ,  Rob Lavigne ,  Guido Volckaert

发明人： Yves Briers ,  Rob Lavigne ,  Guido Volckaert

IPC分类号： C12N9/52 ,  C12N9/36 ,  A61K38/00

CPC分类号： C12N9/2462 ,  A61K38/00 ,  C12N9/52 ,  Y02A50/473 ,  Y02A50/475 ,  Y02A50/478 ,  Y02A50/479 ,  Y02A50/481

摘要： The present invention relates to endolysin variants comprising an endolysin to which a peptide stretch with membrane or LPS disrupting activity is fused. Moreover, the present invention relates to nucleic acid molecules encoding said modified endolysin variant, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, the present invention relates to a method for producing said endolysin variant. Further, the present invention relates to said modified endolysin variant for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means, disinfectant or as cosmetic substance. The present invention also relates to the removal or reduction or prevention of Gram-negative bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries. Furthermore, the present invention relates to the use of said endolysin variant as a diagnostic means in medicinal, food or feed or environmental diagnostic. Finally, the present invention relates to a pharmaceutical composition comprising said modified endolysin variant.

公开(公告)号：US08906365B2

公开(公告)日：2014-12-09

申请号：US13380312

申请日：2010-06-28

申请人： Rob Lavigne ,  Stefan Miller ,  Yves Briers ,  Guido Volckaert ,  Maarten Walmagh

发明人： Rob Lavigne ,  Stefan Miller ,  Yves Briers ,  Guido Volckaert ,  Maarten Walmagh

IPC分类号： C12N9/24 ,  C07K14/005 ,  C07K14/47 ,  C07K19/00 ,  A61K38/47 ,  A61L2/00 ,  C12N15/56 ,  C12N15/62 ,  C12N9/50 ,  C12N15/52 ,  C12N9/36 ,  A61K38/00

CPC分类号： A61K38/47 ,  A61K38/00 ,  A61L2/00 ,  C07K14/005 ,  C07K14/4723 ,  C07K2319/00 ,  C07K2319/20 ,  C12N9/2462 ,  C12N9/503 ,  C12N15/52 ,  C12N15/62 ,  C12Y302/01017 ,  Y02A50/475 ,  Y02A50/478 ,  Y02A50/479

摘要： The application relates to antimicrobial agents against Gram-negative bacteria, in particular to fusion proteins composed of an enzyme having the activity of degrading the cell wall of Gram-negative bacteria and a peptide stretch fused to the enzyme at the N- or C-terminus, as well as pharmaceutical compositions thereof. Moreover, it relates to nucleic acid molecules encoding such a fusion protein, vectors carrying the nucleic acid molecules and host cells transformed with either the nucleic acid molecules or the vectors. In addition, it relates to such a fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means or as cosmetic substance. The application also relates to the treatment or prevention of Gram-negative bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries.

摘要翻译： 本申请涉及抗革兰氏阴性细菌的抗微生物剂，特别是由具有降解革兰氏阴性细菌细胞壁的活性的酶和在N-或C-末端与酶融合的肽拉伸组成的融合蛋白 ，以及其药物组合物。 此外，它涉及编码这种融合蛋白的核酸分子，携带核酸分子的载体和用核酸分子或载体转化的宿主细胞。 此外，它涉及用作药物，特别是用于治疗或预防革兰氏阴性细菌感染的这种融合蛋白，作为诊断手段或化妆品。 该应用还涉及食品加工设备，食品加工厂，与食品接触的表面，医疗器械，医院和手术中的表面的革兰氏阴性细菌污染的治疗或预防。

公开(公告)号：US20120189608A1

公开(公告)日：2012-07-26

申请号：US13390033

申请日：2010-08-24

申请人： Yves Briers ,  Rob Lavigne ,  Maarten Walmagh ,  Stefan Miller

发明人： Yves Briers ,  Rob Lavigne ,  Maarten Walmagh ,  Stefan Miller

IPC分类号： A61K38/47 ,  C07K14/21 ,  C12N1/21 ,  C12N1/19 ,  C12N5/10 ,  A01P1/00 ,  C12N15/63 ,  C12N15/62 ,  A01N37/18 ,  C12Q1/34 ,  A61P31/04 ,  C12N9/24 ,  C12N15/56

CPC分类号： C12N9/2462 ,  A01N43/50 ,  A23L3/3571 ,  A61K38/00 ,  A61K38/47 ,  C07K7/08 ,  C07K14/195 ,  C07K14/21 ,  C07K14/43518 ,  C07K2319/21 ,  C07K2319/55 ,  C12Q1/04 ,  C12Q1/34 ,  C12Y302/01017 ,  G01N2333/928

摘要： The present invention relates to a polypeptide with an amino acid sequence according to SEQ ID NO: 1 and fragments or derivatives thereof. The present invention further relates to fusion proteins comprising said polypeptide and an additional peptide stretch fused to said polypeptide at the N- or C-terminus. Moreover, the present invention relates to nucleic acid molecules encoding said polypeptide or fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, the present invention relates to said polypeptide or fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means, as cosmetic substance or as sanitizing agent. The present invention also relates to the use of said polypeptide or fusion protein for the treatment or prevention of Gram-negative bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries. Furthermore, the present invention relates to a pharmaceutical composition comprising said polypeptide or fusion protein.

摘要翻译： 本发明涉及具有根据SEQ ID NO：1的氨基酸序列及其片段或衍生物的多肽。 本发明还涉及包含所述多肽的融合蛋白和在N-或C-末端与所述多肽融合的另外的肽拉伸。 此外，本发明涉及编码所述多肽或融合蛋白的核酸分子，包含所述核酸分子的载体和包含所述核酸分子或所述载体的宿主细胞。 此外，本发明涉及用作药物的所述多肽或融合蛋白，特别是用作治疗或预防革兰氏阴性细菌感染，作为诊断手段，作为化妆品或消毒剂。 本发明还涉及所述多肽或融合蛋白用于治疗或预防食品的食品加工设备，食品加工厂，与食品接触的表面，医疗器械的革兰氏阴性细菌污染， 在医院和手术中的表面。 此外，本发明涉及包含所述多肽或融合蛋白的药物组合物。

公开(公告)号：US20120189606A1

公开(公告)日：2012-07-26

申请号：US13380312

申请日：2010-06-28

申请人： Rob Lavigne ,  Stefan Miller ,  Yves Briers ,  Guido Volckaert ,  Maarten Walmagh

发明人： Rob Lavigne ,  Stefan Miller ,  Yves Briers ,  Guido Volckaert ,  Maarten Walmagh

IPC分类号： A61K38/46 ,  C12N9/96 ,  C12N15/63 ,  A01N37/46 ,  C12N5/10 ,  C12Q1/34 ,  C12N1/21 ,  A61P31/04 ,  A01P1/00 ,  C12Q1/68 ,  G01N33/53 ,  G01N21/64 ,  C12N15/62 ,  C12N1/19

CPC分类号： A61K38/47 ,  A61K38/00 ,  A61L2/00 ,  C07K14/005 ,  C07K14/4723 ,  C07K2319/00 ,  C07K2319/20 ,  C12N9/2462 ,  C12N9/503 ,  C12N15/52 ,  C12N15/62 ,  C12Y302/01017 ,  Y02A50/475 ,  Y02A50/478 ,  Y02A50/479

摘要： The present invention relates to antimicrobial agents against Gram-negative bacteria, in particular to fusion proteins composed of an enzyme having the activity of degrading the cell wall of Gram-negative bacteria and a peptide stretch fused to the enzyme at the N- or C-terminus. Moreover, the present invention relates to nucleic acid molecules encoding said fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, the present invention relates to said fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means or as cosmetic substance. The present invention also relates to the treatment or prevention of Gram-negative bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries. Furthermore, the present invention relates to a pharmaceutical composition comprising said fusion protein.

摘要翻译： 本发明涉及抗革兰氏阴性细菌的抗微生物剂，特别涉及由具有降解革兰氏阴性细菌细胞壁的活性的酶组成的融合蛋白，以及与N-或C- 终点。 此外，本发明涉及编码所述融合蛋白的核酸分子，包含所述核酸分子的载体和包含所述核酸分子或所述载体的宿主细胞。 此外，本发明涉及用作药物的所述融合蛋白，特别是用于治疗或预防革兰氏阴性细菌感染，作为诊断手段或化妆品物质。 本发明还涉及食品加工设备，食品加工厂，与食品接触的表面，医疗器械，医院和手术中的表面的革兰氏阴性细菌污染的治疗或预防。 此外，本发明涉及包含所述融合蛋白的药物组合物。